: Available data regarding associations between sodium (Na) intake and biomarkers of subclinical arterial damage (SAD) are scarce. This study aimed to investigate the possible associations between Na intake and the 3-year progression of SAD in subjects with cardiovascular disease (CVD) risk factors. : Participants underwent CVD risk assessment, vascular assessment [arterial stiffness by pulse wave velocity (PWV), and atheromatosis, as the existence of carotid and/or femoral plaques], anthropometric measurements [at baseline and 3-year follow-up (FU)], and dietary assessment at FU. : A total of 675 adults (47.9% males, 55.02 ± 13.79 years) were included. Na daily consumption quartiles (Qs) ranged from very low consumption in Q1 (811.72 ± 241.81 mg) up to twice the recommendations in Q4 (3487.92 ± 1025.92 mg). No statistically significant associations were observed between Na intake and changes in SAD biomarkers, after adjustment for age, sex, presence of hypertension, presence of dyslipidemia, smoking, mean arterial pressure, BMI, chronic inflammatory diseases, and energy intake. The results remained the same, even after the assessment of misreporting and the correction of Na intake. : Dietary Na intake was not significantly associated with changes in PWV and carotid or femoral plaques, even in the high Q that was twice as high as the recommended intake. Research in different additional adult cohorts is needed to further investigate whether Na consumption independently affects vascular health.

Download full-text PDF

Source
http://dx.doi.org/10.3390/nu17050808DOI Listing

Publication Analysis

Top Keywords

3-year progression
8
subclinical arterial
8
arterial damage
8
risk factors
8
cvd risk
8
intake
7
dietary sodium
4
consumption
4
sodium consumption
4
consumption 3-year
4

Similar Publications

Autologous stem cell transplantation (ASCT) and chimeric antigen receptor T-cells (CAR-T) have been used as consolidation therapies for patients with refractory/relapsed B cell non-Hodgkin's lymphoma (R/R B-NHL) in remission after second-line chemotherapy or salvage therapy. However, patients with different pathological subtypes and remission states may benefit differently from ASCT or CAR-T cell therapy. Furthermore, consolidation treatment involving ASCT or CAR-T cells still poses a significant risk of disease relapse.

View Article and Find Full Text PDF

This case report describes a geriatric male patient with myasthenia gravis (MG) secondary to giant thymoma, presenting with progressive muscle weakness and ptosis. The diagnosis of MG was confirmed through pathology, imaging, and laboratory evaluations. Considering the significant surgical risks associated with the giant thymoma, adjuvant chemotherapy was initiated.

View Article and Find Full Text PDF

: Available data regarding associations between sodium (Na) intake and biomarkers of subclinical arterial damage (SAD) are scarce. This study aimed to investigate the possible associations between Na intake and the 3-year progression of SAD in subjects with cardiovascular disease (CVD) risk factors. : Participants underwent CVD risk assessment, vascular assessment [arterial stiffness by pulse wave velocity (PWV), and atheromatosis, as the existence of carotid and/or femoral plaques], anthropometric measurements [at baseline and 3-year follow-up (FU)], and dietary assessment at FU.

View Article and Find Full Text PDF

First-Line Tislelizumab Plus Chemotherapy for Advanced Gastric Cancer with Programmed Death-Ligand 1 Expression ≥ 1%: A Retrospective Analysis of RATIONALE-305.

Adv Ther

March 2025

Department of Medical Oncology, State Key Laboratory of Oncology in South China, Collaborative Innovation Center of Cancer Medicine, Sun Yat-sen University Cancer Center, 651 Dong Feng East Road, Guangzhou, 510060, People's Republic of China.

Introduction: Tislelizumab plus investigator-chosen chemotherapy (ICC) demonstrated a statistically significant improvement in overall survival (OS) versus placebo plus ICC in RATIONALE-305 in patients with locally advanced unresectable or metastatic human epidermal growth factor receptor 2 (HER2)-negative gastric cancer/gastroesophageal junction cancer (GC/GEJC) in the intent-to-treat population and in patients with programmed death-ligand 1 (PD-L1) Tumor Area Positivity (TAP) score ≥ 5%. The United States Food and Drug Administration Oncologic Drugs Advisory Committee voted (September 2024) against first-line treatment with programmed cell death protein-1 inhibitors in this setting in patients with a PD-L1 combined positive score < 1 or TAP score < 1%, due to an unfavorable benefit-risk profile. Thus, we retrospectively analyzed data from RATIONALE-305 in patients with a PD-L1 TAP score ≥ 1%.

View Article and Find Full Text PDF

Introduction: The United States Food and Drug Administration Oncologic Drugs Advisory Committee voted (September 2024) against the use of programmed cell death protein-1 inhibitors for first-line treatment of advanced or metastatic unresectable esophageal squamous cell carcinoma (ESCC) with a programmed death-ligand 1 (PD-L1) expression Tumor Area Positivity (TAP) score < 1% or combined positive score < 1 due to an unfavorable benefit-risk profile observed across the phase 3 CheckMate 648, KEYNOTE-590, and RATIONALE-306 trials. Therefore, we conducted a retrospective analysis of RATIONALE-306 to evaluate the efficacy and safety of tislelizumab plus investigator-chosen chemotherapy (ICC) versus placebo plus ICC in patients with advanced or metastatic unresectable ESCC and a PD-L1 TAP score ≥ 1%.

Methods: Adult patients with advanced or metastatic unresectable ESCC enrolled in the global, randomized, phase 3 RATIONALE-306 trial randomly received tislelizumab 200 mg every 3 weeks plus ICC or matched placebo plus ICC.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!